Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 9/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.36 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867217 | 1.00 | GLS (0.41) | GLSCYP17A1AOC3DRD2PTGDR2 | |
| SCHEMBL4867227 | 1.00 | GLS (0.41) | GLSCYP17A1AOC3DRD2PTGDR2 | |
| SCHEMBL5545440 | 0.89 | AOC3 (0.35) | GLSCYP17A1AOC3 | |
| SCHEMBL5545441 | 0.89 | AOC3 (0.35) | GLSCYP17A1AOC3 | |
| SCHEMBL4873464 | 0.86 | CYP17A1 (0.46) | GLSCYP17A1AOC3DRD2MAPKAPK2 | |
| SCHEMBL3936306 | 0.84 | GLS (0.43) | GLSCYP17A1AOC3DRD2PTGDR2 | |
| SCHEMBL3933206 | 0.84 | GLS (0.43) | GLSCYP17A1AOC3DRD2PTGDR2 | |
| SCHEMBL3933198 | 0.84 | GLS (0.43) | GLSCYP17A1AOC3DRD2PTGDR2 | |
| SCHEMBL5547030 | 0.83 | AOC3 (0.45) | AOC3 | |
| SCHEMBL5547027 | 0.83 | AOC3 (0.45) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | GLS 2685/4885CYP17A1 3237/4885AOC3 782/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | GLS 3054/4885CYP17A1 3226/4885AOC3 85/4885 |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | GLS 3831/4885CYP17A1 3261/4885AOC3 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.